Elon Musk says Neuralink plans to implant its first experimental Blindsight devices within 6 to 12 months.
If that happens, the company moves from helping paralyzed patients control computers to something more ambitious: trying to give blind people a form of sight.
What Blindsight is supposed to do
Blindsight tries to skip the camera and the cable entirely. The brain-computer interface aims to restore visual perception by stimulating the visual cortex directly.
Blindsight targets people who are not suitable candidates for retinal or optic-nerve solutions.
Musk announced on August 4, 2026 that human implants were planned within 6 to 12 months, contingent upon regulatory approval.
As of late October 2026, no human implantation results for Blindsight have been publicly confirmed.
Expect pixels, not panoramas
Musk has described the initial resolution as akin to “Atari graphics” or “early Nintendo graphics.”
The longer-term ambition is far bolder. The research findings describe the initial output as low-resolution but potentially evolving beyond natural human sight.
The regulatory fast lane
The device received FDA Breakthrough Device Designation on September 17, 2024.
That designation is meant to speed up the review process for promising medical technologies. It does not confirm that a device is safe or that it works.
Earlier updates indicated successful long-term testing of similar devices in monkeys, with one animal carrying an implant for three years as of mid-2025.
Background: Neuralink’s existing patient base
The company’s N1 implant, its motor-control device, had been placed in 21 participants worldwide by January 28, 2026.
Those devices are built to read signals from the brain so patients can control external devices. Blindsight flips the direction: instead of reading from the brain, it needs to write information into it.
What this means
For patients, the stakes are the most concrete. People who cannot benefit from retinal or optic-nerve treatments currently have few options, and even crude artificial vision would represent a new category of help.
For the broader neurotechnology sector, the research findings suggest successful human trials could boost interest and funding in neurotech ventures.
The milestones to watch are straightforward. First, whether regulators grant the approval the timeline hinges on. Second, whether Neuralink announces its first Blindsight implant within the stated window. Third, what the first patients actually report seeing.
Disclosure: This article was edited by Diego Almada Lopez. For more information on how we create and review content, see our Editorial Policy.